Table 2.
Characteristics of 289 patients, stratified by timing of androgen deprivation therapy (ADT): no ADT, ADT ending before radiotherapy (RT) (ADTEnd < RTEnd), ADT ending after RT but before 1 year post-RT (RTEnd < 1 year) or ADT continuing past 1 year post-RT (ADTEnd ≥ 1 year)
| Characteristic | All, n = 289 | No ADT, n = 22 | ADTEnd < RTEnd, n = 136 | ADTEnd < 1 year, n = 58 | ADTEnd ≥ 1 year, n = 73 |
|---|---|---|---|---|---|
| Total dose (Gy) | |||||
| Median | 67 | 67 | 66.5 | 67 | 73.8 |
| Range | 57–78 | 57–76 | 62–78 | 64–76 | 64–78 |
| Number of Fx EBRT | |||||
| Median | 27 | 27.5 | 27 | 27 | 37 |
| Range | 23–41 | 23–38 | 23–39 | 23–38 | 23–41 |
| Duration EBRT (days) | |||||
| Median | 42 | 43 | 41 | 40 | 51 |
| Range | 30–79 | 30–58 | 30–79 | 30–56 | 31–70 |
| Duration RT (days) | |||||
| Median | 50 | 50 | 49 | 50 | 51 |
| Range | 33–80 | 36–72 | 33–79 | 35–61 | 36–80 |
| Age (years) | |||||
| Median | 66 | 64 | 66 | 64.5 | 67 |
| Range | 44–83 | 52–76 | 49–83 | 44–80 | 53–79 |
| iPSA (ng ml−1) | |||||
| Median | 12.1 | 8.4 | 11.8 | 13.1 | 15.4 |
| Range | 0.3–80.7 | 0.6–61.1 | 0.3–71.3 | 2.3–80.7 | 2.4–64.0 |
| Clinical T-stage, n (%) | |||||
| T1b–T1c | 111 (38) | 10 (45) | 59 (43) | 18 (31) | 24 (33) |
| T2a–T2c | 175 (61) | 12 (55) | 76 (56) | 39 (67) | 48 (66) |
| Missing | 3 (1) | 0 (0) | 1 (1) | 1 (2) | 1 (1) |
| NCCN risk, n (%) | |||||
| Low | 53 (18) | 9 (41) | 28 (21) | 9 (16) | 7 (10) |
| Int. | 105 (36) | 5 (23) | 61 (45) | 15 (26) | 24 (33) |
| High | 131 (45) | 8 (36) | 47 (35) | 34 (59) | 42 (58) |
| Gleason total, n (%) | |||||
| 2–7 | 217 (75) | 18 (82) | 101 (74) | 48 (83) | 50 (68) |
| 8–10 | 30 (10) | 3 (14) | 9 (7) | 6 (10) | 12 (16) |
| Missing | 42 (15) | 1 (5) | 26 (19) | 4 (7) | 11 (15) |
| Whole pelvis EBRT, n (%) | |||||
| Yes | 105 (36) | 7 (32) | 46 (34) | 21 (36) | 31 (42) |
| No | 184 (64) | 15 (68) | 90 (66) | 37 (64) | 42 (58) |
ADTEnd, end of ADT; EBRT, external beam radiation therapy; Fx, fraction; NCCN, National Comprehensive Cancer Network; RTEnd, end of RT.
“iPSA” is the patient's largest prostate-specific antigen measurement before commencing RT, and “NCCN risk” is the National Comprehensive Cancer Network risk category.